Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

• A. Lester ^[2] ; R. Rapkins ^[2] ; S. Nixdorf ^[2] ; M. Khasraw ^[1] ; K. McDonald ^[2]
  1. [1] University of Sydney

     University of Sydney

     Australia

     
  2. [2] University of NSW, Australia
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 3 (March 2017), 2017, págs. 273-278
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.